Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 4

Interventions

Rituximab 7Pyridostigmine Bromide 5Prednisone 5efgartigimod alfa 4Hizentra 4telitacicept 3Immunoglobulins, Intravenous 3Cyclophosphamide 3Azathioprine 3thymoglobulin 2fludarabine 2Thymectomy 2Steroids 2Mycophenolic Acid 2Data Collection 2Blood Specimen Collection 2zilucoplan 1tofacitinib 1tocilizumab 1talquetamab 1sargramostim 1rozanolixizumab 1prednylidene 1gamma-Globulins 1deltacortene 1carmustine, poliferprosan 20 drug combination 1bu-zhong-yi-qi-tang 1apraclonidine 1Walk Test 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Myasthenia Gravis × efgartigimod alfa × Clear all
NCT07072988 2025-09-24

OPTIMAGE

Centre Hospitalier Universitaire de Nice

Phase 4 Recruiting
50 enrolled

Myasthenia Gravis

NCT06765161 2025-07-29

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Clinique Neuro-Outaouais

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

NCT06587867 2024-09-19

Seronegative Myasthenia Gravis - Efgartigimod IV

University Health Network, Toronto

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

NCT06221501 2024-01-24

Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡